|
|
Article: Instrument firms test diagnostics market.
- Article from:
- Instrument Business Outlook
- Article date:
- June 30, 2007
CopyrightCOPYRIGHT 2007 Strategic Directions International Inc. (SDI). This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Recent acquisitions have highlighted the evolving relationship of instrument companies and the molecular diagnostics market. Last month, QIAGEN acquired Digene, the largest provider of human papillomavirus (HPV) diagnostics tests, for $1.6 billion (see IBO 6/15/07). Earlier this year, Agilent acquired Stratagene for $246.2 million (see IBO 4/15/07). These developments follow acquisitions last year by Luminex (see IBO 12/15/06), QIAGEN (see IBO 10/31/07), and Fisher Scientific (now Thermo Fisher Scientific) (see IBO 3/31/06), as well as Applied Biosystems' deal with Celera for rights to sell instruments to the diagnostics market (see IBO 1/15/06). Conversely, the world's ...